Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients-Reference-Cited by-同舟云学术

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

Published:2013-02-28 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Owers Daniel S¹,Webster Angela C²³⁴,Strippoli Giovanni FM²⁴⁵⁶⁷,Kable Kathy⁸,Hodson Elisabeth M²⁹

Affiliation:

1. Australian National University; Australian National University Medical School; Canberra ACT Australia 0200

2. The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006

3. The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145

4. The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145

5. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100

6. Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy

7. Diaverum; Medical-Scientific Office; Lund Sweden

8. Westmead Hospital; Department of Renal Medicine and Transplantation; Darcy Rd Westmead NSW Australia 2145

9. The Children's Hospital at Westmead; Centre for Kidney Research; Locked Bag 4001 Westmead NSW Australia 2145

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD005133.pub3/fullpdf

Reference199 articles.

1. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy;Brennan;Journal of the American Society of Nephrology,1997

2. Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients;Brennan;Transplantation Proceedings,1997

3. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir;Brennan;Journal of Infectious Diseases,2000

4. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation;Gerna;Transplantation,2008

5. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation;Jung;Transplantation Proceedings,2001

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of cytomegalovirus infection after liver transplantation;World Journal of Transplantation;2024-09-18

2. The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation;Transplantation Direct;2024-07-26

3. Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients;Transplant International;2024-05-09

4. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients;Cochrane Database of Systematic Reviews;2024-05-03

5. Clinical impact and risk factors for cytomegalovirus infection in deceased donor liver transplantation without prophylaxis: Single center experience;Annals of Liver Transplantation;2024-04-03